PF-04995274

• Description :

  PF-04995274 is a potent, high-affinity, orally active and partial serotonin 4 receptor (5-HT4R) agonist. PF-04995274 has an EC50 range of 0.26-0.47 nM for human 5-HT4A/4B/4D/4E (Ki range of 0.15-0.46 nM), and has an EC50 range of 0.59-0.65 nM for rat 5-HT4S/4L/4E (Ki of 0.30 nM for rat 5-HT4S) . PF-04995274 is brain penetrant and can be used for cognitive disorders associated with Alzheimer's disease[1][2][3].

• UNSPSC :

  12352005

• Hazard Statement :

  H302-H315-H319

• Target :

  5-HT Receptor

• Type :

  Reference compound

• Related Pathways :

  GPCR/G Protein; Neuronal Signaling

• Applications :

  Neuroscience-Neurodegeneration

• Field of Research :

  Neurological Disease

• Assay Protocol :

  https://www.medchemexpress.com/pf-04995274.html

• Concentration :

  10mM

• Purity :

  99.95

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  OC1(CN2CCC(COC3=NOC4=CC=CC(O[C@H]5COCC5)=C34)CC2)CCOCC1

• Molecular Formula :

  C23H32N2O6

• Molecular Weight :

  432.51

• Precautions :

  P264-P270-P280-P302+P352-P305+P351+P338-P330-P362+P364-P501

• References & Citations :

  [1]Chen BK, et al. Prophylactic efficacy of 5-HT4R agonists against stress. Neuropsychopharmacology. 2019 Oct 10.|[2]Grimwood S, et al. Translational receptor occupancy for the 5-HT4 partial agonist PF-04995274 in rats, non-human primates and healthy volunteers. Alzheimer’s Dement: J Alzheimer’s Assoc. 2011;7:S653.|[3]Timothy Nicholas1, et al. Systems pharmacology modeling in neuroscience: Prediction and outcome of PF-04995274, a 5-HT4 partial agonist, in a clinical scopolamine impairment trial. Advances in Alzheimer's Disease. Vol.2 No.3 (2013) .

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 1

• Isoform :

  Apolipoprotein D

• CAS Number :

  [1331782-27-4]